Cartilage-binding fusion proteins

A technology of fusion protein and cartilage tissue, applied in the direction of fusion polypeptide, peptide/protein component, animal/human protein, etc., can solve the problem of unmet need for effective treatment of joint degenerative diseases

Inactive Publication Date: 2015-12-09
MERRIMACK PHARMACEUTICALS INC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, there is a significant unmet need for effective treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cartilage-binding fusion proteins
  • Cartilage-binding fusion proteins
  • Cartilage-binding fusion proteins

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0164] Example 1: Methods for protein expression and purification

[0165] Method for transient production of protein in 293F cells

[0166] The nucleic acid encoding the desired protein sequence was cloned into the pCep4 vector (Invitrogen) using standard recombinant DNA technology. The transformed NEB5-α competent Escherichia coli (New England Biolabs (New England Biolabs) was selected in 1 L of Luria Broth in the presence of ampicillin (ampicillin) selection at 37°C under shaking at 2000 rpm). )) Cultivate overnight to expand the cloned vector. The cells are harvested and used by spinning at 5000g for 20 minutes Plasmid MegaKit (Qiagen) to extract vector DNA from bacterial pellets. By adding 20 mL of 200 mM L-glutamine (source?) and 10 mL of 10% Pluronic F-68 to 1 L of F17 medium ( ) To prepare 293F cell culture medium. For transient transfection, at 37°C and 5% CO 2 Let 1L of 293F cells grow to a density of 1.5-2 million cells / ml. 1 mg of total protein and 2.5 mL of pol...

Example Embodiment

[0178] Example 2: Combination of fusion protein with heparan sulfate and chondroitin sulfate

[0179] The specificity of the binding of the fusion protein to the polysaccharides heparan sulfate and chondroitin sulfate can be determined by measuring the ability of the protein to bind to the polysaccharide coated on the ELISA plate. Coat the heparin binding plate (BDBiosciences) with 50μl of heparan sulfate or chondroitin sulfate (2-10μg / mL). ) And incubate overnight at room temperature. The plate was washed with PBS and blocked with 250 μl of PBS containing 0.2% gelatin at 37°C for 1 hour. The plate was then washed with PBS and patted dry. A dilution series of 50 μl protein was added to the wells and incubated at 37°C for 2 hours. The protein dilution series started at 100 nM and included 10 additional three-fold dilutions in PBS, 0.2% gelatin, and a blank control (only PBS, 0.2% gelatin). After washing the plate in PBS, 50 μl of anti-human IGF-1 (Abcam) (in PBST, 1:250) was ...

Example Embodiment

[0181] Example 3: Binding of fusion protein to collagen II

[0182] The specificity of the protein to type II collagen can be determined by measuring the ability of the protein to bind to the collagen coated on the ELISA plate. will The 96-well plate was coated with 100 μl of type II collagen (Chondrex Products, Redmond, WA) at 4° C. with 1× the provided buffer overnight. The plate was washed with PBS, 0.05% Tween-20 (PBST) and blocked with 100 μl of protein-free blocking buffer (Pierce, Thermo Scientific) for 1 hour at room temperature. The plate was then washed with PBST and patted dry. A dilution series of 50 μl protein was added to the well and incubated for 1 hour at room temperature. The protein dilution series started at 100 μM and included 10 additional three-fold dilutions in PBS and a blank control (PBS). After the plate was washed in PBS, 50 μl of anti-human IGF-1 (Abcam) (in PBST, 1:250) was added and the plate was incubated for 1 hour at room temperature with ro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided.

Description

[0001] related application [0002] This application claims priority to US Provisional Application 61 / 806,599, filed March 29, 2013, which is hereby incorporated by reference in its entirety. Background technique [0003] Traumatic joint injury (eg, tearing of ligaments, tendons, and cartilage) triggers a multifactorial degenerative cascade within joint tissue, including a chronic cycle of inhibition of tissue repair, upregulation of extracellular matrix catabolism, cell death, and joint degeneration. Although some aspects of joint damage can be repaired through surgical tissue grafting procedures, these approaches may only partially restore the biomechanical stability of the joint. Current treatments, including surgery and palliative care, are insufficient to prevent permanent changes in joint motion. Such alterations affect the effects of physical forces and changes in cell or tissue mechanics (ie, mechanobiological effects), including alterations in cellular signaling, wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/00
CPCA61K31/573A61K9/0024A61K9/127A61K38/00A61K38/1709A61K38/30A61P19/02A61P19/08A61P19/10A61P29/00A61K2300/00A61K9/0019A61K9/5015C07K14/47C07K14/65C07K2319/74
Inventor E·弗洛林D·B·科波汀P·科佩斯基A·卢戈维斯科R·伦纳德B·舍贝尔
Owner MERRIMACK PHARMACEUTICALS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products